Compare Novartis AG (NVS) vs Realty Income Corp (O) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Realty Income Corp — how do they compare? Novartis AG trades at $142.04 (market cap $274.00B), while Realty Income Corp trades at $54.2 (market cap $50.48B). The key difference: Novartis AG is far larger — about 5.4× Realty Income Corp's market cap, and Realty Income Corp pays the higher dividend (6.11%). Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Realty Income Corp for 127 Days on average.
| NVS | O | |
|---|---|---|
Market Cap | $274.00B | $50.48B |
Volume | 1,852,137 | 6,493,749 |
Sector | Health | Real Estate |
52-Week High | $168.62 | $67.56 |
52-Week Low | $121.80 | $53.35 |
Typical Hold Time | 82 Days | 127 Days |
Enterprise Value | $315.32B | $81.11B |
Dividend Yield | 3.31% | 6.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.11, up 1.65% with mixed technical signals showing neutral momentum. The company maintains strong profitability with 22.5% net margins and recently announced a $7.8B licensing deal with China's Abogen. Recent earnings show two beats and one miss in the last three quarters, with Q3 2026 results pending. The stock trades below the consensus price target of $146, suggesting modest upside potential from current levels.
Novartis presents a balanced investment case with strong cash flow generation and profitability offset by recent clinical setbacks and M&A scrutiny. The $7.8B Abogen partnership expands the autoimmune pipeline, but investors face risks from patent cliffs and drug development failures. Analyst consensus leans cautious with 68% hold ratings, reflecting uncertainty around pipeline execution amid ongoing strategic repositioning.
Realty Income (O) trades at $54.17, down 0.15% with a bearish technical signal. The stock faces pressure from rising Treasury yields but maintains strong fundamentals including 92.56% gross margins and consistent dividend payments. Recent earnings have missed expectations, though revenue growth continues with 2025 reaching $5.75B. Analyst consensus remains positive with a $64.80 price target despite technical weakness.
The stock offers income potential with its 6%+ dividend yield and 136 consecutive dividend increases, but faces headwinds from interest rate sensitivity and recent earnings misses. Long-term fundamentals remain solid with A-rated credit and near-99% occupancy, though near-term technical pressure suggests cautious entry points.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Realty Income Corp
Realty Income owns roughly 11,400 properties, most of which are freestanding, single-tenant, triple-net-leased retail properties. Its properties are located in 49 states and Puerto Rico and are leased to 250 tenants from 47 industries. Recent acquisitions have added industrial, office, manufacturing, and distribution properties, which make up roughly 17% of revenue.
Read more on O →
